Indian Panel Revises Bharat Vaccine Approval Amid 'Objections'
Executive Summary
Bharat Biotech's quadrivalent (DPT-Hib) vaccine will have to go through Phase III trials after rival Panacea Biotec questions India's market authorization of the product.